Global Sepsis Therapeutics Industry

Global Sepsis Therapeutics Industry

  • April 2021 •
  • 72 pages •
  • Report ID: 6051306 •
  • Format: PDF
Abstract:
- Global Sepsis Therapeutics Market to Reach $765 Million by 2027
- Amid the COVID-19 crisis, the global market for Sepsis Therapeutics estimated at US$14.8 Million in the year 2020, is projected to reach a revised size of US$765 Million by 2027, growing at a CAGR of 75.7% over the period 2020-2027.
- The U.S. Market is Estimated at $4.6 Million, While China is Forecast to Grow at 71.8% CAGR
- The Sepsis Therapeutics market in the U.S. is estimated at US$4.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.6 Million by the year 2027 trailing a CAGR of 71.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 67.9% and 64.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 51.3% CAGR.

- Select Competitors (Total 24 Featured) -
  • Adrenomed AG
  • AM-Pharma B.V.
  • Aridis Pharmaceuticals Inc.
  • Asahi Kasei Pharma America
  • Astellas Pharma Inc.
  • Endacea Inc.
  • InflaRx GmbH
  • La Jolla Pharmaceutical Company
  • Opsonix, Inc.
  • T2 Biosystems Inc.
  • TaiRx Inc.